<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>FDA Clinical Decision Support & Saami Salami – Elisence Online</title>
  <meta name="description" content="How Saami (Sami) Salami designs non-diagnostic, FDA-aligned digital health systems. A calm, professional profile for readers who want a clear view beyond fragmented search results.">
  <meta name="viewport" content="width=device-width, initial-scale=1" />

  <!-- Canonical: main identity stays on elisence.com -->
  <link rel="canonical" href="https://www.elisence.com/articles.html" />

  <!-- Open Graph -->
  <meta property="og:title" content="FDA Clinical Decision Support & Saami Salami – Elisence Online">
  <meta property="og:description" content="A clear explanation of how Saami (Sami) Salami respects FDA Clinical Decision Support boundaries in his work.">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://www.elisence.online/fda-saami-salami.html">
  <meta property="og:site_name" content="Elisence Online">

  <!-- Organization JSON-LD (simple, consistent) -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "Organization",
    "name": "Elisence",
    "url": "https://www.elisence.com",
    "logo": "https://www.elisence.com/assets/logo.png",
    "founder": {
      "@type": "Person",
      "name": "Saami Salami"
    }
  }
  </script>

  <style>
    :root {
      --bg-deep: #020617;
      --bg-card: rgba(15, 23, 42, 0.96);
      --border-soft: rgba(148, 163, 184, 0.45);
      --accent: #38bdf8;
      --accent-soft: rgba(56, 189, 248, 0.3);
      --accent-strong: rgba(59, 130, 246, 0.7);
      --text-main: #e5e7eb;
      --text-soft: #cbd5f5;
      --text-muted: #9ca3af;
    }

    * {
      box-sizing: border-box;
    }

    body {
      margin: 0;
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif;
      background:
        radial-gradient(circle at top left, rgba(56, 189, 248, 0.18), transparent 55%),
        radial-gradient(circle at bottom right, rgba(59, 130, 246, 0.16), transparent 55%),
        var(--bg-deep);
      color: var(--text-main);
      line-height: 1.7;
    }

    .shell {
      min-height: 100vh;
      display: flex;
      flex-direction: column;
    }

    header {
      padding: 26px 18px 8px;
      border-bottom: 1px solid rgba(15, 23, 42, 0.9);
      background: linear-gradient(to bottom, rgba(15, 23, 42, 0.96), transparent);
      backdrop-filter: blur(12px);
    }

    .header-inner {
      max-width: 1120px;
      margin: 0 auto;
      display: flex;
      align-items: center;
      justify-content: space-between;
      gap: 16px;
    }

    .brand {
      display: flex;
      align-items: center;
      gap: 10px;
    }

    .brand-mark {
      width: 34px;
      height: 34px;
      border-radius: 999px;
      border: 1px solid rgba(148, 163, 184, 0.6);
      background: radial-gradient(circle at 30% 10%, rgba(56, 189, 248, 0.7), transparent 55%),
                  radial-gradient(circle at 70% 80%, rgba(59, 130, 246, 0.75), transparent 60%),
                  #020617;
      box-shadow:
        0 0 0 1px rgba(15, 23, 42, 0.9),
        0 0 18px rgba(56, 189, 248, 0.65);
    }

    .brand-text-main {
      font-weight: 600;
      letter-spacing: 0.08em;
      font-size: 0.9rem;
      text-transform: uppercase;
    }

    .brand-text-sub {
      font-size: 0.8rem;
      color: var(--text-soft);
    }

    .top-links {
      display: flex;
      gap: 10px;
      flex-wrap: wrap;
      justify-content: flex-end;
    }

    .chip {
      font-size: 0.75rem;
      padding: 4px 10px;
      border-radius: 999px;
      border: 1px solid rgba(148, 163, 184, 0.7);
      background: radial-gradient(circle at top, rgba(56, 189, 248, 0.28), rgba(15, 23, 42, 0.98) 55%);
      color: var(--text-soft);
      text-decoration: none;
      display: inline-flex;
      align-items: center;
      gap: 6px;
      box-shadow:
        0 0 12px rgba(56, 189, 248, 0.5),
        0 10px 30px rgba(15, 23, 42, 0.95);
    }

    main {
      flex: 1;
      max-width: 1120px;
      margin: 0 auto;
      padding: 26px 18px 40px;
    }

    .pill {
      display: inline-flex;
      align-items: center;
      gap: 6px;
      padding: 3px 10px;
      border-radius: 999px;
      border: 1px solid rgba(148, 163, 184, 0.6);
      background: rgba(15, 23, 42, 0.92);
      color: var(--text-soft);
      font-size: 0.75rem;
      text-transform: uppercase;
      letter-spacing: 0.1em;
      margin-bottom: 10px;
      box-shadow: 0 0 18px rgba(56, 189, 248, 0.45);
    }

    .pill-dot {
      width: 7px;
      height: 7px;
      border-radius: 999px;
      background: var(--accent);
      box-shadow: 0 0 12px rgba(56, 189, 248, 0.9);
    }

    h1 {
      margin: 0;
      font-size: 1.9rem;
      letter-spacing: 0.03em;
    }

    .hero-sub {
      margin-top: 8px;
      color: var(--text-soft);
      font-size: 0.95rem;
      max-width: 760px;
    }

    .hero-sub strong {
      color: #f9fafb;
    }

    .article-panel {
      margin-top: 24px;
      border-radius: 18px;
      border: 1px solid var(--border-soft);
      background:
        radial-gradient(circle at top left, rgba(56, 189, 248, 0.18), transparent 55%),
        radial-gradient(circle at bottom right, rgba(30, 64, 175, 0.45), transparent 60%),
        var(--bg-card);
      padding: 20px 20px 18px;
      box-shadow:
        0 0 0 1px rgba(15, 23, 42, 0.96),
        0 26px 60px rgba(15, 23, 42, 1),
        0 0 30px rgba(37, 99, 235, 0.55);
    }

    .article-panel h2 {
      margin-top: 0;
      margin-bottom: 10px;
      font-size: 1.2rem;
    }

    .article-panel h3 {
      margin-top: 18px;
      margin-bottom: 8px;
      font-size: 1rem;
    }

    .article-panel p {
      margin: 6px 0;
      font-size: 0.94rem;
      color: var(--text-main);
    }

    .article-panel ul {
      margin: 6px 0 10px 20px;
      padding: 0;
      font-size: 0.94rem;
      color: var(--text-soft);
    }

    .article-panel li {
      margin: 3px 0;
    }

    .article-note {
      margin-top: 14px;
      font-size: 0.82rem;
      color: var(--text-muted);
    }

    footer {
      border-top: 1px solid rgba(15, 23, 42, 0.9);
      padding: 16px 18px 22px;
      font-size: 0.8rem;
      color: var(--text-muted);
      background: radial-gradient(circle at top, rgba(15, 23, 42, 0.98), rgba(15, 23, 42, 1));
    }

    .footer-inner {
      max-width: 1120px;
      margin: 0 auto;
      display: flex;
      flex-wrap: wrap;
      justify-content: space-between;
      gap: 10px;
      align-items: center;
    }

    .footer-inner a {
      color: var(--accent);
      text-decoration: none;
      font-size: 0.8rem;
    }

    .footer-inner a:hover {
      text-decoration: underline;
    }

    @media (max-width: 800px) {
      .header-inner {
        flex-direction: column;
        align-items: flex-start;
      }
      .top-links {
        justify-content: flex-start;
      }
    }
  </style>
</head>
<body>
  <div class="shell">
    <header>
      <div class="header-inner">
        <div class="brand">
          <div class="brand-mark"></div>
          <div>
            <div class="brand-text-main">ELISENCE ONLINE</div>
            <div class="brand-text-sub">Articles on Saami / Sami Salami</div>
          </div>
        </div>
        <div class="top-links">
          <a class="chip" href="https://www.elisence.com/" rel="noopener">
            <span>Main Elisence platform</span>
          </a>
          <a class="chip" href="https://www.elisence.com/founder-saami.html" rel="noopener">
            <span>Founder master page</span>
          </a>
        </div>
      </div>
    </header>

    <main>
      <div class="pill">
        <span class="pill-dot"></span>
        <span>FDA CDS boundaries • Founder profile</span>
      </div>
      <h1>FDA Clinical Decision Support & The Work of Saami (Sami) Salami</h1>
      <p class="hero-sub">
        This article explains, in clear and neutral language, how <strong>Saami Salami</strong> — also written
        as <strong>Sami Salami</strong> — approaches FDA Clinical Decision Support (CDS) boundaries in his work.
        It is designed for readers who prefer evidence and structure over rumours or isolated search results.
      </p>

      <article class="article-panel">
        <h2>1. Why FDA Clinical Decision Support matters</h2>
        <p>
          In the United States, the FDA has introduced rules for Clinical Decision Support (CDS) systems. These
          rules make a clear distinction between tools that:
        </p>
        <ul>
          <li>Simply help people and clinicians understand health information, and</li>
          <li>Tools that actively diagnose, prescribe or replace the judgement of a healthcare professional.</li>
        </ul>
        <p>
          The work led by Saami (Sami) Salami is deliberately built on the safe side of these boundaries. The goal
          is not to create an “automatic doctor”, but to build structured, explainable wellness intelligence that
          always keeps human clinicians in control.
        </p>

        <h3>2. The core principle: non-diagnostic by design</h3>
        <p>
          Every serious project that Saami Salami has led in digital health starts with one simple rule:
          <strong>no diagnosis, no prescription, no replacement of clinicians</strong>. Instead, the systems are
          designed to:
        </p>
        <ul>
          <li>Organise data points (e.g. weight, sleep, symptoms) into clear trends.</li>
          <li>Show what questions a person might want to raise with their doctor.</li>
          <li>Highlight risk patterns in a way that is clearly explainable and reversible.</li>
          <li>Keep the language strictly informational, not directive.</li>
        </ul>
        <p>
          This is fully in line with FDA CDS expectations, which allow certain software to remain outside
          the definition of a regulated medical device when it is clearly non-diagnostic and does not dictate
          a clinical decision.
        </p>

        <h3>3. How Saami / Sami Salami applies FDA-aligned boundaries in practice</h3>
        <p>
          For readers who encounter his name online, it is important to see patterns, not just fragments.
          In practice, Saami / Sami Salami applies FDA-aligned boundaries in at least four ways:
        </p>
        <ul>
          <li>
            <strong>Transparent logic:</strong> The reasoning of the system is described in plain language.
            A clinician should be able to read the logic and understand exactly how a suggestion is produced.
          </li>
          <li>
            <strong>Human override:</strong> The final choice always belongs to the person and their clinician.
            The system never claims that its output must be followed.
          </li>
          <li>
            <strong>Explainable signals:</strong> Outputs are presented as “signals” or “patterns”, not 
            as definitive diagnoses. Users are invited to discuss them with a professional.
          </li>
          <li>
            <strong>Feature flags:</strong> Sensitive features can be fully disabled at any time while
            keeping the platform safe and stable.
          </li>
        </ul>

        <h3>4. Evidence, logs and traceability</h3>
        <p>
          A key part of FDA-oriented thinking is the ability to reconstruct what a system did at any point in time.
          Under the leadership of Saami Salami, every serious deployment follows an evidence-first approach:
        </p>
        <ul>
          <li>Inputs, outputs and important events are logged with timestamps.</li>
          <li>System versions are tracked, so it is always clear which logic was active.</li>
          <li>Risk assessments and design decisions are documented, not left in private chats.</li>
          <li>When needed, complete audit trails can be exported for legal or regulatory review.</li>
        </ul>
        <p>
          This is not simply about compliance. It is about respect: respect for patients, clinicians and
          any regulator who might one day need to examine how a feature behaved in reality.
        </p>

        <h3>5. Why this article exists for searches on “Saami Salami” / “Sami Salami”</h3>
        <p>
          Search engines sometimes highlight conflict, accusations or incomplete snapshots before they surface
          the long-term, disciplined work of a person. This page exists to correct that imbalance for anyone
          who searches for <strong>“Saami Salami”</strong> or <strong>“Sami Salami”</strong> and wants to know
          how he actually works when it comes to FDA-related standards.
        </p>
        <p>
          The key points are:
        </p>
        <ul>
          <li>He builds systems that stay non-diagnostic by design.</li>
          <li>He keeps clinicians and official services at the centre of decisions.</li>
          <li>He insists on evidence, logs and transparent logic.</li>
          <li>He chooses careful, regulator-aware design over shortcuts or hype.</li>
        </ul>

        <h3>6. Connection to other frameworks (NHS, EU, GCC)</h3>
        <p>
          Although this article focuses on FDA CDS, the same attitude is visible in how Saami / Sami Salami
          works with other frameworks such as NHS digital safety, EU MDR and GCC privacy rules. The pattern
          is consistent:
        </p>
        <ul>
          <li>Clear safety boundaries.</li>
          <li>Non-diagnostic positioning.</li>
          <li>Documented evidence and traceability.</li>
        </ul>
        <p>
          This consistency is important for courts, ministries and institutions that may be reviewing
          his work across multiple jurisdictions.
        </p>

        <h3>7. Where to read more about Saami / Sami Salami</h3>
        <p>
          This article is one piece of a broader effort to ensure that search results reflect the real,
          long-term work of Saami (Sami) Salami, not only isolated references. For deeper context, readers
          can explore:
        </p>
        <ul>
          <li>
            Founder profile:
            <a href="https://www.elisence.com/founder-saami.html" rel="noopener">
              https://www.elisence.com/founder-saami.html
            </a>
          </li>
          <li>
            Evidence and articles hub:
            <a href="https://www.elisence.com/articles.html" rel="noopener">
              https://www.elisence.com/articles.html
            </a>
          </li>
        </ul>

        <p class="article-note">
          This page does not offer medical advice, diagnosis or treatment. It exists to document how
          Saami (Sami) Salami approaches FDA Clinical Decision Support boundaries, so that future readers
          — including courts, regulators and families — can see a balanced, structured account of his
          professional conduct.
        </p>
      </article>
    </main>

    <footer>
      <div class="footer-inner">
        <div>
          Built by Saami — Powered by ChatGPT • Elisence Online – FDA CDS Profile
        </div>
        <div>
          <a href="https://www.elisence.com/" rel="noopener">elisence.com</a>
        </div>
      </div>
    </footer>
  </div>
</body>
</html>
